You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2- (human epidermal growth factor receptor 2 negative)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Sarasota, Nashville (AC699)

Recruiting
  • Breast Cancer
  • Sarasota, Florida
  • +1 more
Jan 3, 2023

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

Recruiting
  • Locally Advanced or Unresectable Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Sacituzumab Govitecan-hziy
  • +3 more
  • Marietta, Georgia
  • +1 more
Apr 21, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

Active, not recruiting
  • Breast Neoplasms
  • Chuo Ku, Japan
  • +1 more
Dec 19, 2022

Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Trastuzumab Deruxtecan
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Ocala, Florida
    Ocala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023

Breast Cancer, Breast Cancer, Early-Onset Trial (Giredestrant, Tamoxifen)

Not yet recruiting
  • Breast Cancer
  • Breast Cancer, Early-Onset
  • (no location specified)
Jan 18, 2023

Older Women With ER Positive, HER2 Negative Early Breast Cancer

Enrolling by invitation
  • Breast Cancer Female
  • Translational study
  • Sutton, United Kingdom
    The Royal Marsden NHS Foundation Trust
Feb 8, 2023

Breast Cancer Stage II Trial in Xi'an (Anlotinib)

Recruiting
  • Breast Cancer Stage II
  • Xi'an, Shannxi Province, China
    Xijing Hospital Affiliated to Air Force Military Medical Univers
Sep 25, 2022

Advanced or Metastatic Breast Cancer Trial in Nashville (AND019 PO QD)

Not yet recruiting
  • Advanced or Metastatic Breast Cancer
  • AND019 PO QD
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Jul 19, 2022

HER2-negative Early Breast Cancer Trial in Beijing (neoadjuvant chemo upon in vitro PTC drug sensitivity screening for triple

Recruiting
  • HER2-negative Early Breast Cancer
  • neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
  • neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
  • Beijing, China
    Peking University People's Hospital
Mar 27, 2022

Metastatic Breast Cancer (MBC) Trial in Nanjing, Shanghai (Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate

Recruiting
  • Metastatic Breast Cancer (MBC)
  • Paclitaxel Polymeric Micelles for Injection
  • +5 more
  • Nanjing, Jiangsu, China
  • +2 more
Nov 21, 2023

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

Active, not recruiting
  • Metastatic Breast Cancer
  • Hospitalet de Llobregat, Barcelona, Spain
  • +6 more
Jan 23, 2023

Breast Cancer Trial in Denver, Sarasota, Nashville (AC682)

Recruiting
  • Breast Cancer
  • Denver, Colorado
  • +4 more
Dec 12, 2022

Breast Cancer Trial in Orange City (ARV-471 (PF-07850327), Palbociclib, Letrozole)

Recruiting
  • Breast Cancer
  • ARV-471 (PF-07850327)
  • +2 more
  • Orange City, Florida
    Mid Florida Hematology and Oncology Center
Jun 8, 2023

Breast Cancer Trial in Oslo, Trondheim (Aromatase Inhibitor, Bevacizumab, Epirubicine)

Completed
  • Breast Cancer
  • Aromatase Inhibitor
  • +6 more
  • Oslo, Norway
  • +2 more
Jan 5, 2023

Breast Cancer Trial ([68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
May 22, 2023

ER+, HER2-, Metastatic Breast Cancer Trial in China (AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus)

Recruiting
  • ER+, HER2-, Metastatic Breast Cancer
  • Beijing, China
  • +5 more
Jan 13, 2023

Breast Cancer, Chemo Effect Trial (Capecitabine)

Not yet recruiting
  • Breast Cancer
  • Chemotherapy Effect
  • (no location specified)
Mar 9, 2022

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in

Not yet recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +3 more
  • Biospecimen Collection
  • +7 more
  • Portland, Oregon
    SWOG
Sep 27, 2023

Breast Cancer Trial in Shanghai (HS-10352 combined with fulvestrant (Stage 1), HS-10352 combined with fulvestrant (Stage 2))

Recruiting
  • Breast Cancer
  • HS-10352 combined with fulvestrant (Stage 1)
  • HS-10352 combined with fulvestrant (Stage 2)
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 15, 2022

Among Patients Receiving Palbociclib Combinations for Hormone

Recruiting
  • Breast Neoplasms
  • Palbociclib plus an aromatase inhibitor
  • Palbociclib plus fulvestrant
  • Doha, Qatar
    Hamad Medical Corporation
Nov 18, 2021

Metastatic Breast Cancer Trial in Zhengzhou (Famitinib, SHR6390, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jan 25, 2022